Obsidian Therapeutics

Nov 18, 2020

Obsidian Therapeutics & MD Anderson announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL(TM)) for solid tumors

Sep 17, 2020

Obsidian Therapeutics Appoints Jan ter Meulen, M.D., Ph.D., as Chief Scientific Officer

May 01, 2020

Obsidian Therapeutics Develops and Shares Safe Workplace Productivity Solution in Response to COVID19

Mar 03, 2020

Obsidian Therapeutics Appoints Anders Götzsche to Board of Directors